Regulated medical device programs require OEMs to evaluate, approve, and periodically re-evaluate their suppliers against defined criteria. For composite components used in FDA-regulated devices, those criteria cover process capability, quality system infrastructure, material control, and documentation — and the evidence for each must be documented, not asserted. A composite manufacturer with commercial program experience that has not built its quality system around regulated production requirements is not positioned to support these programs, no matter how strong its fabrication capability may be.
This post describes what medical OEM engineering and quality teams typically evaluate when qualifying a composite manufacturing partner, and what the documented evidence for each criterion generally involves. CMI’s medical device composite manufacturing capability—FDA-registered and ISO 13485 compliant—is built to meet these qualification requirements.
ISO 13485 is the international standard for quality management systems specific to medical device manufacturing. Most medical OEM supplier evaluations treat ISO 13485 certification as a baseline qualification requirement for composite suppliers entering regulated programs. ISO 13485 certification means a third-party registrar has audited the supplier’s quality management system against the standard’s requirements and issued a certificate of compliance.
Beyond the certificate itself, OEM quality teams may examine how long the supplier has maintained certification, whether recent surveillance audits produced any findings, and whether the scope of the certificate covers the specific manufacturing operations relevant to the program.
Depending on the supplier’s activities and role in producing the finished device, FDA establishment registration may apply. When applicable, registration is a facility-level requirement through which an establishment notifies the FDA of its medical device manufacturing activities. OEM quality teams may request the supplier’s FDA registration information and current registration status as part of the supplier qualification process.
Medical composite programs typically require complete material traceability from incoming material certification through finished part documentation. OEM quality teams evaluate supplier material control by examining documented procedures for:
Suppliers who respond to these questions with verbal assurances rather than documented procedures are generally not positioned to support the traceability requirements of regulated programs.
Process control is what produces consistent composite parts. OEM quality teams evaluate whether the supplier has documented, controlled layup and cure procedures for the specific part geometry and material system; whether cure cycles are monitored and recorded; whether the supplier has a documented nonconformance and corrective action process; and what process validation exists for the manufacturing methods the OEM’s program requires. CMI’s composite manufacturing and assembly operations are built around documented process controls designed to support regulated program requirements.
First article inspection (FAI) documentation is a standard deliverable for medical composite programs. OEM quality teams confirm that the supplier can produce a first article inspection report covering all critical characteristics defined in the drawing and specification. For ongoing production, OEM quality teams evaluate the inspection records the supplier generates for each production run and how those records are maintained and available for audit.
Medical composite programs often require engineering collaboration before the manufacturing phase begins — design-for-manufacturability review, laminate design input, material selection guidance. OEM quality teams may evaluate whether the supplier has in-house engineering capability to support this collaboration, or whether they are a fabrication-only operation that requires the OEM to provide a fully developed design. CMI’s in-house design and engineering team and co-molding capability support OEM programs that require engineering collaboration from design review through production. For programs requiring custom component development, CMI’s custom composite engineering capability covers the full design-to-production scope.
A complete medical OEM composite supplier qualification record typically documents each criterion above: QMS certification status and scope, FDA registration confirmation, material control procedure review, process control and validation evidence, FAI capability confirmation, and engineering collaboration capability assessment. Suppliers that can provide documented evidence for each criterion before the qualification audit may shorten the qualification timeline and reduce the risk of findings that delay program start.
